Ginkgo Bioworks Holdings (DNA) Intangibles (2020 - 2026)
Ginkgo Bioworks Holdings' (DNA) quarterly Intangibles came in at $48.9 million in Q1 2026, down 28.94% YoY from $68.8 million in Q1 2025, and down 8.64% on a QoQ basis from $53.5 million in Q4 2025.
Ginkgo Bioworks Holdings (DNA) Intangibles (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has 7 years of Intangibles data on file, last reported at $48.9 million in Q1 2026.
- Quarterly Intangibles fell 28.94% year-over-year to $48.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $48.9 million (down 28.94% YoY) and the FY2025 annual result came in at $53.5 million, down 26.24% from the prior year.
- Intangibles fell to $48.9 million in Q1 2026, from $53.5 million in the prior quarter.
- In the past five years, Intangibles ranged from a high of $111.0 million in Q4 2022 to a low of $20.8 million in Q1 2022.
- A 5-year average of $72.6 million and a median of $72.5 million in 2024 frame the typical range for Intangibles.
- Annual changes were most pronounced in 2023 — Intangibles jumped 422.04% — and 2026, when it dropped 28.94%.
- Tracing DNA's Intangibles over 5 years: stood at $111.0 million in 2022, then retreated by 25.49% to $82.7 million in 2023, then decreased by 12.37% to $72.5 million in 2024, then slipped by 26.24% to $53.5 million in 2025, then decreased by 8.64% to $48.9 million in 2026.
- The last three Intangibles figures came in at $48.9 million (Q1 2026), $53.5 million (Q4 2025), and $61.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Ginkgo Bioworks Holdings | 432.60 Mn | 348.06 Mn | 18.44 Mn | 44.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 44.39 Mn |
| Mar 31, 2026 | 48.86 Mn |
| Dec 31, 2025 | 53.48 Mn |
| Sep 30, 2025 | 61.52 Mn |
| Jun 30, 2025 | 66.15 Mn |
| Mar 31, 2025 | 68.76 Mn |
| Dec 31, 2024 | 72.51 Mn |
| Sep 30, 2024 | 79.57 Mn |
| Jun 30, 2024 | 90.60 Mn |
| Mar 31, 2024 | 77.41 Mn |
| Dec 31, 2023 | 82.74 Mn |
| Sep 30, 2023 | 100.17 Mn |
| Jun 30, 2023 | 105.03 Mn |
| Mar 31, 2023 | 108.74 Mn |
| Dec 31, 2022 | 111.04 Mn |
| Sep 30, 2022 | 47.94 Mn |
| Jun 30, 2022 | 39.18 Mn |
| Mar 31, 2022 | 20.83 Mn |
| Dec 31, 2021 | 21.64 Mn |
| Sep 30, 2021 | 22.57 Mn |